Next Bio-Research Services has officially began operations in the Ironbridge Medical Park in Chester, Va. The company continues a 23-year history of providing comprehensive integrated project support to investigators in the biotech and pharmaceutical sectors and in providing medical testing services to physicians using state-of-the-art platforms.

Next Bio was founded by three long-term friends and colleagues who collectively have more than 100 years of experience in R&D activities. Startup funds for the new company were identified through a “friends and family” raise, which includes the three founders and two passive investors.

Initially, Next Bio will focus on providing pharmacogenomics molecular genetic testing, as well as certain cancer genetic and enzyme therapeutic assays. Each of the test platforms fall under the umbrella of personalized health, and are meant to help physicians guide their treatments based on an individual’s genetic make-up.

“We are excited by the launch of our new company, and by the opportunity to provide sophisticated technologies for our customers,” said Next Bio President Tom Reynolds. “Our mission is to deliver essential research and clinical support services and solutions in innovative and cost effective ways, and in so doing, protect and further the health, safety and privacy of our customer patients.”

Next Bio-Research Services is a comprehensive CRO offering drug discovery, drug development, and clinical testing services to customers in the biotech and pharma industries, and to doctors, hospitals, clinics and private patients.